Skip to main content
Skip to footer
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Start
>
News
>
Regulatory
>
MAR
MAR
Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851
Kancera appoints Peter Selin as new Chief Executive Officer
Interim report for first quarter 2021, 1 January – 31 March 2021
Interim report for the second quarter 2020. January 1st – June 30th, 2020
Interim report for the second quarter 2019, 1 January – 30 June 2019
INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January – 31 March 2019
INTERIM REPORT FOR KANCERA AB (publ) 1st January – 30th September 2018
Time plan for Kancera’s rights issue
YEAR END REPORT KANCERA AB (publ) 1st January – 31st December 2017
Kancera performs the second partial payment for the Fractalkine project